Kawa Chiu
Chief Technical Officer Abdera Therapeutics
Kawa Chiu is the CTO at Abdera Therapeutics, a biopharmaceutical company pioneering precision radiopharmaceuticals through antibody engineering for cancer. Under her leadership, Abdera developed ABD-147 and ABD-320, Actinium-225 therapeutics with companion Indium-111 imaging pairs targeting DLL3 and 5T4-expressing tumors. ABD-147 received FDA Fast Track and Orphan Drug designations in 2024.
Seminars
• Discussing how to preserve, recruit and keep your talent
• Identifying key bottlenecks from CMC to clinical personnel
• Exploring how to encourage and nurture new talent in the field: including pharma and academic involvement
• Using real-world clinical outcomes to provide insights into patient populations, treatment efficacy and long-term safety
• Enhancing trial design through optimal patient selection, dosing strategies and endpoints
• Guiding potential personalized treatment strategies
